Project: A multi-omic stratification and a non invasive tool for early recognition of triple negative and Her2+ breast cancer patients responders to neoadjuvant therapy
| Acronym | PORTRAIT (Reference Number: ERAPERMED2022-114) |
| Project Topic | Neoadjuvant therapy (NAT) is the standard initial treatment for Triple Negative (TN) and Her2+ Breast cancer. Despite the similar clinical presentation, the tumor response to NAT diverges widely due to the influence of several individual factors - including microbiota - which have a crucial role in immune response and in conditioning molecular pathways. Thus, a systematic and integrated stratification of the patients at the onset of the disease, together with the evaluation of the common decision-making criteria, will help a better recognition of responders and the design of new personalized therapeutic plans improving patient care and quality of life. PORTRAIT aims to create a multidimensional ID of responders vs. non responders which will integrate host characteristics and clinical data with tissue and distal microbiota characteristics (gut and skin microbiota). It also aims to create a non-invasive predictive tool based on innovative omics approaches such as volatilomics and proteomics other than NGS. Furthermore, it aims to test personalized approaches in 3D models to highlight the interaction between the components and define the individual panel of determinants affecting the therapeutic outcome. After a characterization of the host and tumor microbiota on a retrospective cohort by omics approaches (WP2), a multidimensional characterization will be performed before and after NAT in a prospective cohort, expanding the observation to gut, skin and tumor microenvironment (WP3) together with metabolomics and volatilomics. All data and patients characteristics will be integrated through Systems Biology algorithms to identify predictors and implement a non-invasive tool based on volatilome (WP4). The impact of microbiota on NAT treatment will be ultimately tested on 3D models (WP5). The compliance with the data protection requirements and the GDPR will be guaranteed, and new models of analysis of ethico-legal questions surrounding organoid will be implemented (WP6). |
| Network | ERA PerMed |
| Call | 5th Joint Transnational Call for Proposals (2022) |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" | Coordinator | Italy |
| 2 | University of Navarra | Partner | Spain |
| 3 | Inserm, Regional northwest agency | Partner | France |
| 4 | IRCCS Centro di Riferimento Oncologico di Aviano National cancer Institute | Partner | Italy |
| 5 | Foundation for Biosanitary Research in Eastern Andalusia | Partner | Spain |
| 6 | University of Heidelberg | Partner | Germany |
| 7 | Hadassah Medical Organization | Partner | Israel |